The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 15 - 2024 |
doi: 10.3389/fmicb.2024.1440090
Frontiers in Cellular and Infection Microbiology
Provisionally accepted
Carla L. Abán
1*
Silvia Orosco
1*
Julio N. Argañaraz Aybar
1*
Leonardo Albarracin
2
Analía Venecia
1*
Liliana Perret
1*
Sonia Ortiz Mayor
1*
Keita Nishiyama
3
Juan C. Valdéz
1*
Haruki Kitazawa
3
Julio Villena
2*
Nadia Gobbato
1*- 1 Universidad Nacional de Tucumán, San Miguel de Tucumán, Tucumán, Argentina
- 2 Laboratory of Immunobiotechnology, CONICET Reference Centre for Lactobacilli (CERELA), Tucuman, Argentina
- 3 Tohoku University, Sendai, Miyagi, Japan
The aim of this work was to investigate the effect of the cell free supernatant of Lactiplantibacillus plantarum ATCC ® 10241 TM on the capacity of Pseudomonas aeruginosa strains isolated from cystic fibrosis (CF) patients to form biofilms. In addition, the study evaluated in vivo the ability of the cell free supernatant to modulate inflammation and reduce lung damage in mice infected with the P. aeruginosa strains or challenged with P. aeruginosa and Streptococcus milleri group (SMG). Results showed that CF-derived P. aeruginosa strains can infect the respiratory tract of adult mice inducing local inflammation and lung damage. The severity of the infection is exacerbated when P. aeruginosa is administered with SMG. Of note, the nebulization with the cell free supernatant of L. plantarum induced beneficial effects in the respiratory infection and inflammatory response induced by P. aeruginosa alone or with SMG. Reduced bacterial loads and lung damage were observed in supernatant-treated mice compared to controls. Although further mechanistic studies are necessary, the results show that the cell free supernatant of L. plantarum ATCC ® 10241 TM is an interesting adjuvant alternative to treat P. aeruginosa respiratory infections and superinfections in CF patients.
Keywords: lactiplantibacillus plantarum, supernatant, respiratory infection, Pseudomonas aeruginosa, Cystic Fibrosis
Received: 28 May 2024; Accepted: 06 Aug 2024.
Copyright: © 2024 Abán, Orosco, Argañaraz Aybar, Albarracin, Venecia, Perret, Ortiz Mayor, Nishiyama, Valdéz, Kitazawa, Villena and Gobbato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Carla L. Abán, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Silvia Orosco, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Julio N. Argañaraz Aybar, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Analía Venecia, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Liliana Perret, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Sonia Ortiz Mayor, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Juan C. Valdéz, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Julio Villena, Laboratory of Immunobiotechnology, CONICET Reference Centre for Lactobacilli (CERELA), Tucuman, 4000, Argentina
Nadia Gobbato, Universidad Nacional de Tucumán, San Miguel de Tucumán, T4000INI, Tucumán, Argentina
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.